AUS
NZ
UK
CA
USA
IND
Highlights
Clinical Trial Advancement: Hemogenyx Pharmaceuticals is nearing the launch of a Phase I trial for its lead asset, HEMO-CAR-T, aimed at treating acute myeloid leukemia (AML).
-
Strategic Partnerships: The first patient will be treated at the MD Anderson Center in Texas, with the University of Pennsylvania expressing interest in future participation.
-
Diverse Therapeutic Pipeline: The company is advancing multiple promising therapies, including its Chimeric Bait Receptor (CBR) platform and the CDX program, targeting various health challenges.
Description
Hemogenyx Pharmaceuticals PLC {LSE:HEMO} is on the cusp of initiating a Phase I clinical trial for its innovative CAR-T therapy, HEMO-CAR-T, which is designed to combat acute myeloid leukemia (AML). In a recent update accompanying its interim results, the company confirmed that the renowned MD Anderson Center in Texas will administer treatment to the first patient. Additionally, the University of Pennsylvania has expressed a strong interest in participating in the trial, although this involvement may not commence until the end of the year.
HEMO-CAR-T represents a next-generation chimeric antigen receptor T-cell therapy that enhances the body's immune response by reprogramming T-cells to identify and eliminate cancer cells. This innovative approach offers a potential curative treatment option for AML, distinguishing it in the healthcare landscape.
The pharmaceutical industry’s growing interest in advanced CAR-T therapies has led to significant milestone and royalty payments from major companies such as AstraZeneca, Johnson & Johnson, AbbVie, and Novartis, underscoring the commercial viability of these treatments.
In addition to HEMO-CAR-T, Hemogenyx is actively developing its CBR platform, which aims to reprogram immune cells, such as macrophages, to combat viral infections and specific cancer types. Initially targeting viruses like COVID-19, the CBR platform has shown promise in treating rare cancers, including epithelial ovarian carcinoma. Research is ongoing to refine the stability of mRNA-based CBRs for enhanced effectiveness, with potential intranasal delivery methods being explored for airborne infections.
Furthermore, the company is progressing its CDX program, which assists AML patients in preparing for bone marrow transplants. An improved version of CDX, utilizing bispecific pairing technology, has demonstrated increased efficacy in laboratory settings and is currently undergoing animal studies to pave the way for clinical trials.
For the six months ending June 30, the company reported a loss, primarily due to its commitment to research and development efforts. Hemogenyx exited this period with a stable cash position, supporting its ongoing initiatives in the dynamic field of immunotherapy.
